Kiudro (Mesalazine)

Mesalazine inhibits the cyclooxygenase and lipoxygenase pathways in the intestinal mucosa, lowering the production of prostaglandins and leukotrienes. This suppression of inflammatory mediators reduces colonic inflammation and promotes healing of the bowel lining.

The dosage of Kiudro is determined by the prescribing clinician based on the severity of the disease, patient weight, and response to therapy. Healthcare professionals tailor the regimen to each individual, and patients should follow the specific instructions provided by their prescriber.

Safety of mesalazine during pregnancy or lactation has not been definitively established. Physicians weigh potential benefits against possible risks before prescribing Kiudro to pregnant or nursing women, and patients should discuss their situation with a healthcare provider.

To request Kiudro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kiudro (mesalazine) is a locally acting aminosalicylate, whereas alternatives such as corticosteroids or biologics act systemically. Mesalazine generally has a more favorable safety profile for mild to moderate disease, but may be less potent for severe cases where stronger immunosuppressive agents are required.

Kiudro should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability and effectiveness.

Kiudro is administered rectally, typically as an enema or suppository, depending on the specific formulation supplied. The patient follows the prescriber's instructions regarding the volume, frequency, and duration of each rectal dose.

Serious risks include severe allergic reactions, significant gastrointestinal bleeding, liver toxicity, pancreatitis, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms like rash, blood in stool, jaundice, or unexplained abdominal pain.

Individuals with known hypersensitivity to mesalazine or other aminosalicylates should avoid Kiudro. It is also contraindicated in patients with severe ulcerative colitis requiring systemic therapy, and caution is advised for those with compromised renal or hepatic function.